Scott Filler, M.D. is Professor of Medicine, David Geffen School of Medicine, and Chief, Division of Infectious Diseases, Harbor-UCLA Medical Center. He completed his undergraduate education at Dartmouth College in Hanover, New Hampshire, where he graduated Magna cum Laude. He then received his medical degree from the UCLA School of Medicine, and performed an internship and residency in internal medicine before completing a fellowship in infectious diseases at Harbor-UCLA Medical Center. His research focuses on the mechanisms by which pathogens including Candida albicans and Aspergillus fumigatus invade and damage human cells, causing life-threatening infections. Dr. Filler and his team discovered the first two fungal invasins. Dr. Filler has authored or co-authored more than 150 peer-reviewed papers, book chapters and reviews. He is inventor on 3 U.S. patents of pharmaceutical compositions to vaccinate against disseminated candidiasis.
Mike Gresser, Ph.D. is Chief Scientific Officer for ImmuneGene, the Myelin Repair Foundation, and is a Lecturer in the Honors Program in the College of Letters and Science at UCLA. He serves on or chairs the scientific advisory boards of several biotechnology companies. From 2000-2006, Dr. Gresser served as Vice President, Research for Inflammation at Amgen, Inc. Prior to Amgen, he was at the Merck Frosst Center for Therapeutic Research where he rose to be Executive Director of Biochemistry and Molecular Biology. His team was responsible for the introduction of Singulair, Vioxx, and Arcoxia to the clinical market. Dr. Gresser received his Ph.D in Biochemistry from Brandeis University and did postdoctoral studies at the Molecular Biology Institute at UCLA under Nobel Laureate Paul D. Boyer. Before joining Merck Frosst in 1988, Dr. Gresser was Professor of Chemistry at Simon Frazer University in Burnaby, British Columbia where he was on the faculty for 8 years.
Paul McCray, Jr., M.D. received a B.A. in Biology from St. Olaf College and an M.D. from the University of Iowa. He completed residency training in pediatrics and a pediatric pulmonary fellowship at the University of Iowa. He is Professor of Pediatrics, Microbiology, and Internal Medicine at the University of Iowa. He is the Executive Vice Chair in the Department of Pediatrics, Associate Director of the Center for Gene Therapy of Cystic Fibrosis, and holds the Roy J. Carver Chair in Pulmonary Research. He is a member of the American Society for Clinical Investigation, the American Pediatric Society, the Association of American Physicians, the American Association for the Advancement of Science, and the American Academy of Microbiology. As a pediatric pulmonologist, Dr. McCray has long-standing interests in cystic fibrosis, host-pathogen interactions, airway epithelial biology, pulmonary innate immune responses, and the applications of gene transfer for lung diseases. One focus of his laboratory program has been to better understand the pathogenesis of cystic fibrosis as a path to new treatments. Another focus is the study of virulent coronavirus infections (SARS, MERS, COVID-19), their pathogenesis, the development of small animal models of disease, and paths to therapies. Dr. McCray’s work is supported by NIH and the Cystic Fibrosis Foundation. Dr. McCray has authored or co-authored more than 220 peer-reviewed papers, book chapters, and reviews
Charles L. Bevins, M.D., Ph.D., is Professor of Microbiology and Immunology, School of Medicine, University of California, Davis. He completed his education at the University of Maryland, graduating with honors, receiving the system-wide Michael J. Pelczar Award for Excellence in Graduate Studies, and recently honored as a Distinguished Alumnus. He completed internship and residency training in pediatrics at UCSF Medical Center, and then his clinical fellowship and postdoctoral research training at the National Institutes of Health, Bethesda MD. His research focuses on the roles of epithelial defensin peptides, fundamental effector molecules of innate immunity, in mediating host-microbe interactions in the mammalian respiratory, gastrointestinal and reproductive tracts. Dr. Bevins has served as Principal Investigator of NIH-funded investigations in this area continuously since 1991, and was recently honored with a NIH MERIT Award. The Bevins laboratory draws credit for several key contributions to the field, including: discovery, purification, and cloning of numerous defensins; establishing several fundamental in vivo functions of defensins in terms of both protection from bacterial pathogens and shaping the composition of the commensal microbiota, and elucidating the involvement of defensins in the pathogenesis of Crohn’s disease and necrotizing enterocolitis. Dr. Bevins has authored or co-authored more than 150 peer-reviewed papers, book chapters and reviews, which have been cited by over 8,500 scientific articles, and he is co-inventor on 6 U.S. patents. Outside of the laboratory, Dr. Bevins has received awards for both teaching and mentorship.